Aptevo Therapeutics Announces Reverse Stock Split

Aptevo Therapeutics ( (APVO) ) has issued an update.

On May 22, 2025, Aptevo Therapeutics received a notice from Nasdaq indicating non-compliance with the minimum stockholders’ equity requirement, giving the company until July 7, 2025, to submit a compliance plan. Additionally, Aptevo announced a 1-for-20 reverse stock split to maintain Nasdaq listing standards, effective May 23, 2025, with trading on a split-adjusted basis starting May 27, 2025.

The most recent analyst rating on (APVO) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.

Spark’s Take on APVO Stock

According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.

Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.

To see Spark’s full report on APVO stock, click here.

More about Aptevo Therapeutics

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for cancer treatment. The company has two clinical candidates, Mipletamig and ALG.APV-527, targeting acute myeloid leukemia and multiple solid tumors, respectively. Aptevo’s pipeline is built on proprietary platforms ADAPTIR® and ADAPTIR-FLEX®.

Average Trading Volume: 5,002,895

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.51M

See more data about APVO stock on TipRanks’ Stock Analysis page.